110
Largest Single Human Trial
Duke glioma RCT (Peters 2022) — placebo-controlled, double-blind
0
Completed Phase 3 Efficacy RCTs
None in PubMed or ClinicalTrials.gov for LDN cancer efficacy — funded trials terminated early (n=7 enrolled)
20+
Preclinical Cancer Studies
Animal + cell line data across colorectal, cervical, glioma, pancreatic, hepatocellular models
$30–50
Monthly Cost (Compounded)
vs $10,000–15,000+/mo for targeted therapy or immunotherapy
Where the Evidence Actually Stands
PubMed
Trials
The honest picture: robust preclinical science, a handful of human case series with striking individual outcomes, one null Phase 2 RCT (QoL endpoint, not survival), and zero funded Phase 3 trials — not because LDN was tested and failed, but because a 40-year-old generic with no patent generates no sponsor.
What Preclinical Science Actually Shows
Animal / Cell Line
PubMed
LDN's anti-cancer mechanism hypothesis operates through 3 converging pathways — each documented in peer-reviewed preclinical literature. None has been confirmed in a powered human trial. These are the best-understood mechanisms; they are not confirmed effects in patients.
OGF-OGFr Rebound Axis
↑ OGFr
Brief nightly blockade of opioid growth factor receptor (OGFr) triggers compensatory upregulation of OGFr density and OGF (met-enkephalin) synthesis. Result in preclinical models: OGF → inhibits cancer cell proliferation. Documented in hepatocellular carcinoma (P16/P21 activation), colorectal, and Ehrlich carcinoma models.
Immune Reprogramming (M1 Macrophages)
↑ IFN-γ
LDN increases IFN-γ secretion and shifts tumor-associated macrophage balance toward anti-tumor M1 phenotype while reducing myeloid-derived suppressor cells (MDSCs). In colorectal cancer mouse model: LDN activated Bax/Bcl-2/caspase-3/PARP apoptosis cascade, reducing tumor volume.
PI3K/AKT/mTOR Suppression
PI3K↓
In cervical cancer cell lines, LDN suppressed PI3K/AKT/mTOR signaling pathway (a major cancer survival and proliferation pathway) and inhibited epithelial-mesenchymal transition (EMT), which drives metastasis. Indirect effects on tumor-associated macrophages also observed in vivo.
LDN + Chemo Combination Signal
BCL2↓↓
In Ehrlich carcinoma mice, LDN + 5-fluorouracil (5-FU) produced maximal downregulation of the anti-apoptotic mediator BCL2 — greater than either agent alone. LDN solo also increased OGFr expression and IFN-γ levels, suggesting immune + apoptotic additive effect. Design: 5 groups, 12 mice each.
Preclinical ≠ Human. Every one of these findings is in cell lines or rodent models. Mechanisms that work in vitro or in mice fail to translate to humans in most oncology contexts. These findings explain WHY researchers are interested in LDN for cancer — they do not establish that LDN works in people.
Every Human Study — The Full Honest Table
PubMed
ClinicalTrials.gov
All PMIDs below are live-verified against NCBI esummary (title-match gate passed 2026-07-29). Every claim matches the actual paper title and abstract.
| # | Study | Type | n | Primary Finding | Outcome |
|---|---|---|---|---|---|
| 1 | Peters KB et al. 2022 — "Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial" (PMID 35001215). Duke University. NCT01303835. | Phase 2 RCT Placebo-controlled |
110 | LDN 4.5 mg/night vs placebo during concurrent radiation + temozolomide. QoL (FACT-Brain) and fatigue (FACIT-Fatigue) change from baseline. | Null — no significant QoL or fatigue difference vs placebo. Similar adverse event profiles. Endpoint: QoL, not survival/tumor response. |
| 2 | Malik A, Ye A, Chung M. 2025 — "Low Dose Naltrexone for Refractory Cancer Pain: Case Series of Initial Safety and Effectiveness" (PMID 40849024). MD Anderson Cancer Center. | Case Series Pain endpoint |
20 | Cancer patients with refractory pain, prescribed LDN 1.5–4.5 mg/day (most common max: 3.0 mg). 45% breast cancer. 10 cancer burden pain, 10 therapy-related pain. Follow-up ~65 days (visit 1), ~105 days (visit 2). | 80% (16/20) reported improvement at first follow-up; 76.9% (10/13) at second. Minor adverse events: 2 patients (insomnia, GI upset). Discontinuation rate 15%. Conflict: one author speaking fees from Saluda Medical. |
| 3 | Berkson BM, Rubin DM, Berkson AJ. 2009 — "Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases" (PMID 20042414). Integrative Cancer Therapies. | Case Series ALA + LDN protocol |
3 new (4 total incl. 2006) | ALA (intravenous) + oral LDN + lifestyle. Patients had failed or declined standard treatment. PET scan outcomes reported. | GB: alive 39 months; JK: "PET demonstrated no evidence of disease" at 5 months; RC: "PET no signs of cancer" at 4 months. Design limits: multi-modal protocol (ALA cannot be disaggregated from LDN), case series, n=3, no control arm, self-selected patients. |
| 4 | Berkson BM, Rubin DM, Berkson AJ. 2006 — "The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol" (PMID 16484716). Integrative Cancer Therapies. | Case Report ALA + LDN |
1 | Pancreatic adenocarcinoma + liver metastases. University oncology center had given "little hope." Started ALA/LDN protocol October 2002. | Alive 78+ months post initial presentation; "back at work, free from symptoms, without appreciable progression." Design limits: single case, multi-modal protocol, no control. |
| 5 | Berkson BM et al. 2018 — "The Long-Term Survival of a Patient With Stage IV Renal Cell Carcinoma Following an Integrative Treatment Approach Including the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol" (PMID 29258346). Integrative Cancer Therapies. | Case Report ALA + LDN |
1 | Stage IV renal cell carcinoma; ALA/LDN integrative protocol. | Long-term survival documented. Same design limits as 2006/2009 papers. |
| 6 | Miskoff JA, Chaudhri M. 2018 — "Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion" (PMID 30197847). Cureus. Jersey Shore University Medical Center. | Case Report NSCLC + hx prostate CA |
1 | 50-year-old male, history of prostate and lung cancer, prolonged survival. LDN as complementary medication. No competing interests declared. | Prolonged survival noted; authors attribute benefit to LDN's immune-augmenting mechanism. Single case, cannot establish causation. |
| 7 | McKenzie-Brown AM, Khanna N, Singh V. 2022 — "Low-Dose Naltrexone in Endometrial Intraepithelial Neoplasia" (PMID 34240210). Pain Medicine. | Case Report | 1 | Endometrial intraepithelial neoplasia; LDN used. Published in a pain medicine journal, suggesting pain was also an indication. | Outcome favorable in this single case. Pre-cancerous condition, not invasive malignancy. |
Reality Check: The strongest human study (Duke glioma RCT, n=110) found no significant benefit on QoL/fatigue. It was designed to test QoL — not tumor response, not survival. The compelling individual outcomes (Berkson's pancreatic cancer cases) come from multi-modal protocols that cannot isolate LDN's individual contribution. The striking numbers are real; the design limits mean they cannot be interpreted as LDN alone working.
Active & Planned Trials: NCT07224009 (Phase 2, LDN for fatigue in prostate cancer patients on ADT) — NOT YET RECRUITING as of 2026-07-29. ClinicalTrials.gov NCT07224009 →
Cost vs. Oncology Alternatives
Market Data · July 2026
LDN is not a replacement for proven cancer treatments. But the cost asymmetry is load-bearing context: a $30-50/month off-patent compound has no industry sponsor for the trial that would prove or disprove it. The cost comparison also helps any reader weighing adjunct use.
Off-Patent Generic
LDN (Compounded 4.5 mg/night)
$30–50
per month, no insurance
Standard Chemo
Chemotherapy (varies by regimen)
$1K–10K
per month, highly variable
Immune Checkpoint
Pembrolizumab (Keytruda / PD-1)
~$150K+
per year, WAC price; individual varies with insurance
Targeted Therapy
Ibrutinib (Imbruvica / BTK)
~$12–15K
per month at WAC before insurance/assistance
Integrative
Integrative Oncology Consult
$200–500
per visit; varies widely by provider
Follow the Money — Why No Definitive Trial Exists
Funding Context
💰 The Structural Funding Gap — Not Censorship, But a Real Problem
Naltrexone's US patent expired in 1984. Any company can manufacture it. There is no exclusivity, no monopoly profit, no incentive for the $50M–$300M investment a Phase 3 cancer RCT requires. The compound that would benefit most from a proven oncology indication — LDN's compounding pharmacy network — lacks the capital. The pharmaceutical companies whose oncology revenues LDN might threaten have every reason NOT to fund it.
This is not censorship. No FDA warning letter targets LDN. No medical board actions against LDN prescribers have been found for cancer use. The primary mechanism here is a structural funding gap — and "no large Phase 3 RCT" is a funding finding, not a scientific verdict that LDN doesn't work.
1984
Year naltrexone patent expired — over 40 years off-patent
$300M
Typical cost of a Phase 3 oncology RCT — no one profits from funding it
7
Patients enrolled in NCT01650350 (targeted: melanoma/prostate/RCC) before "slow enrollment" stopped it
NCT01650350 Termination (primary record, ClinicalTrials.gov): Phase 2 trial in metastatic melanoma, castrate-resistant prostate cancer, and renal cancer — stopped October 24, 2013. Official reason: "Study stopped 10/24/13 secondary to lack of patients/slow enrollment." Not a regulatory shutdown; not stopped for safety signals. The slow enrollment itself tells the story: no industry sponsor, no recruitment infrastructure, no commercial urgency. Primary record →
Dose Protocol — How Clinicians Actually Use It
Clinical Practice
LDN is an oral capsule from a compounding pharmacy — no reconstitution, no injection. The standard protocol for cancer-adjacent use mirrors the general LDN approach. The taper-in reduces sleep disruption side effects. Evidence tier for cancer is "clinical" (prescribing practice) — no RCT has tested dose titration for cancer outcomes.
Weeks 1–2
Start Low
Start Low
1.5 mg
Nightly at bedtime. Allows adjustment to vivid dreams / sleep changes. Compounding pharmacy dispenses at exact dose in capsule form. Must be 7–10 days opioid-free before starting (FDA label).
Evidence tier: Clinical (prescribing practice) — not trial-tested
Weeks 3–4
Step Up
Step Up
3.0 mg
Most common maximum dose in MD Anderson 2025 case series (9 of 20 patients). If sleep disruption persists, stay at 1.5 mg longer. Bedtime timing is important — exploits nocturnal opioid receptor blockade → morning rebound in endorphins/enkephalins.
Evidence tier: Clinical (reported prescribing practice — PMID 40849024)
Week 5+ Maintenance
4.5 mg
Bihari's standard dose; Duke glioma RCT dose. Most protocols target 4.5 mg nightly long-term. "Nontoxic" and "no side effects" (Bihari, 2004) at this dose — but that's private-practice experience, not a formal safety trial.
Evidence tier: Clinical (Bihari private practice; PMID 35001215 Duke RCT)
⛔ Critical Constraint
Opioids
Anyone currently on opioid pain medication (morphine, oxycodone, fentanyl, buprenorphine, methadone, tramadol, codeine, hydrocodone) cannot use LDN. Even the low dose blocks mu-opioid receptors for several hours. This is a real clinical conflict: many cancer patients need opioids for pain. This is not a minor caveat — discuss with your oncologist and pain specialist.
Evidence tier: FDA Label — CONTRAINDICATED (verbatim: "Patients receiving opioid analgesics")
No body-weight dosing, no reconstitution. LDN is prescribed as fixed oral capsules (1.5, 3.0, 4.5 mg) from a compounding pharmacy. The math is straightforward: the pharmacy makes the exact capsule. Unlike injectable peptides, there is no mixing, dilution, or syringe calculation required. Some clinicians use a liquid formulation (1 mg/mL) for finer titration — still no reconstitution needed by the patient.
Regulatory Position
T1 — Regulatory
FDA
Not Approved for Cancer — Off-Label Prescribing Permitted
Naltrexone approved at 50 mg for opioid and alcohol dependence. LDN (1.5–4.5 mg) in cancer is off-label. No FDA safety communication, drug safety alert, or REMS targeting LDN as a product. No IND filed for LDN in cancer as of 2026. FDA label contraindication quoted verbatim: "Patients receiving opioid analgesics." Hepatotoxicity warning in label is based on 300 mg/day (1980s obesity trials) — 67× the maximum LDN dose; no hepatotoxicity reported at 4.5 mg in any trial.
FDA naltrexone label →
ClinicalTrials.gov
2 Historical Trials Closed; 1 Upcoming
NCT01303835 (completed 2011): glioma Phase 2 — published as PMID 35001215 (QoL null result). NCT01650350 (terminated 2013): melanoma/prostate/RCC — stopped at n=7 for slow enrollment. NCT07224009 (prostate ADT fatigue): Phase 2, NOT YET RECRUITING as of 2026-07-29. NCT05307627: withdrawn before enrollment.
ClinicalTrials.gov search →
Compounding Pharmacy Oversight
FDA Oversight of Manufacturing Quality — Not LDN Suppression
FDA warning letters to compounding pharmacies (2018–2024) cited manufacturing quality violations (sterility, potency testing, good manufacturing practices) — standard GMP enforcement not targeting LDN specifically. LDN remains legal to prescribe, compound, and dispense in the US under prescription. Most patients pay out-of-pocket ($30–50/month); insurance rarely covers compounded medications.
FDA compounding Q&A →
PubMed vs. The Doctors Who Used It
PubMed
T-Doc — Credentialed Practitioners
Two equal pillars: what the controlled literature found, and what credentialed clinicians observed in patients. These aren't the same story, and both deserve honest presentation. You decide what to do with the contrast.
The Controlled Literature Says:
PubMed — T1 Evidence
The only placebo-controlled RCT (Duke, n=110 glioma patients, PMID 35001215) found no significant benefit on QoL or fatigue during chemoradiation. The endpoint was QoL — not tumor response, not survival. A 2024 Polish review (PMID 38539570) describes compelling OGF-OGFr science but concludes clinical confirmation is still needed. Expert reviewer Prof. Dalgleish at St George's (PMID 35107043) specifically calls for clinical trials "especially in combination with chemotherapy." The honest read: mechanism plausible, preclinical data consistent, human evidence too sparse to conclude either way.
Dr. Bernard Bihari, MD (1931–2010)
MD (Harvard 1957) · Board-Certified Psychiatry/Neurology (ABPN) · NY License 088158 · Private Practice, NYC
Treated approximately 450 cancer patients with LDN beginning February 1999 — "almost all of whom had failed to respond to standard treatments." As of March 2004, he reported "more than 60% of patients with cancer may significantly benefit from LDN." NCI reviewed 30 charts in June 2002; roughly half "appeared to have responded to LDN without question." Dose: 4.5 mg nightly, compounded capsules. Design limits (stated honestly): retrospective, uncontrolled, private-practice chart review; 96 of 450 patients had missing follow-up data; many seen only once in consultation; data never peer-reviewed as a clinical study. Source: lowdosenaltrexone.org →
Dr. Burton Berkson, MD, PhD
MD/PhD · Internist · New Mexico State University · Published 3 peer-reviewed case series (Integrative Cancer Therapies, Sage)
Published the ALA/LDN protocol in Integrative Cancer Therapies with outcomes including a patient with pancreatic cancer + liver mets alive 78+ months (PMID 16484716), three more pancreatic cancer patients with PET showing "no evidence of disease" (PMID 20042414), and a Stage IV renal cell carcinoma long-term survivor (PMID 29258346). Design limits (stated honestly): ALA + LDN + lifestyle — cannot isolate which component drove outcomes; case series (n=1-3 per paper), no control arm, self-selected patients who sought integrative care. The outcomes are real individual cases; the causal attribution to LDN specifically cannot be established from the data.
Prof. Angus Dalgleish, FRCPath
FRCPath · Professor of Oncology · St George's University of London · Senior Author PMID 35107043
Academic oncologist at a UK research university. Peer-reviewed position (Expert Rev Anticancer Ther 2022): "Considering the increase in the number of anecdotal reports of activity, there will likely be a bigger drive toward using LDN in the oncological setting. These reports support clinical trials of LDN in cancer, especially when given in combination with certain chemotherapy." Advocates for trials — does not assert LDN is proven.
Side Effects — What's Real vs. What's Not
FDA Label
Trial Data
The safety picture at 4.5 mg is substantially different from naltrexone at 50 mg. But the opioid contraindication is absolute and must be the first thing any cancer patient checks.
⛔ ABSOLUTE CONTRAINDICATION — Opioids
FDA-label verbatim: "Contraindicated in patients receiving opioid analgesics." Many cancer patients are on opioids for pain. Even LDN doses block mu-opioid receptors for several hours, which precipitates acute withdrawal and eliminates analgesia. This is not a theoretical risk — naltrexone will override opioid pain management. Anyone on morphine, oxycodone, fentanyl, hydrocodone, tramadol, codeine, buprenorphine, or methadone must NOT use naltrexone without their doctor's explicit guidance. Minimum 7–10 days opioid-free before starting.
✓ Transient: Vivid Dreams / Sleep Disruption
Most common reported side effect at LDN doses. Typically resolves in 1–3 weeks. The taper-in approach (starting at 1.5 mg) reduces this. Some patients prefer to move bedtime dose to early evening if dreams are disruptive. In the Duke glioma RCT (n=110), adverse event profiles were similar between LDN and placebo — adverse events were attributed to concurrent temozolomide, not LDN.
Hepatotoxicity — Label Warning Does NOT Apply at LDN Doses
The FDA label carries a hepatotoxicity note based on 300 mg/day doses in 1980s obesity trials. LDN maximum is 4.5 mg — 67× lower. No trial (including the 110-patient glioma RCT) has reported elevated liver enzymes at LDN doses. Most prescribers still obtain baseline LFTs as precaution; recommended for patients with pre-existing liver disease. The warning is real at the 50 mg approved dose in some settings — it is pharmacologically inapplicable to 4.5 mg.
Safety profile at 4.5 mg is genuinely reassuring — with one exception. Decades of off-label prescribing (fibromyalgia, Crohn's, MS, now cancer) have not surfaced a serious safety signal at LDN doses, beyond the transient sleep side effects. The concern for cancer patients is almost entirely the opioid interaction — that one constraint is not minor and must be resolved with your care team before considering LDN.
Primary-Voice Media — Verified, Not Summarized
Verified via yt-dlp
Both videos confirmed accessible via yt-dlp --skip-download as of 2026-07-29. Metadata (title, uploader, date, views, duration) pulled live — not stated from memory. Financial interests disclosed inline.
▶
The Game Changer, LDN & Cancer — Low Dose Naltrexone Documentary
Financial interest: LDN Research Trust is a UK charity (founded by MS patients) that sells LDN-related conferences, ebooks, and medical memberships; has direct financial interest in promoting LDN. Bias should be weighed accordingly.
youtube.com/watch?v=Af-xpqfYYEI — STATUS: ACCESSIBLE →
▶
Curing Cancer with Low Dose Naltrexone — New Research
Financial interest: Bloor Pain Specialists is a clinical pain practice that prescribes LDN for consultations; financial interest in promoting LDN as a treatment option.
youtube.com/watch?v=E7RJYBMqWPM — STATUS: ACCESSIBLE →
Removal asymmetry: No systematic removal of LDN cancer content found on YouTube as of this search. Both primary videos remain accessible. This is a search result, not an inference. (Contrast with some COVID/ivermectin practitioner content, where deplatforming has been documented.)
The Bottom Line — In Plain English
What it is: Naltrexone is a 1984 FDA-approved generic for opioid/alcohol dependence at 50 mg. Low-dose naltrexone (1.5–4.5 mg, about 1/10th the approved dose) exploits a different pharmacology: brief nightly receptor blockade triggers a compensatory surge in the body's own opioid growth factor and endorphin systems the next morning. In cancer, this OGF-OGFr mechanism appears to inhibit tumor cell proliferation in preclinical models. The immune angle (macrophage reprogramming, IFN-γ, reduction in MDSCs) is equally documented in animal studies.
What the evidence shows: Strong and consistent preclinical science across multiple cancer types. Human evidence is sparse: the best RCT (n=110 glioma, Duke 2022) found no QoL benefit but wasn't designed to test survival or tumor response. The most striking human outcomes come from Berkson's ALA+LDN case series (pancreatic cancer patients alive 39–78+ months) — real documented cases, with the caveat that a multi-modal protocol prevents attributing the outcome to LDN specifically. Bihari's 450-patient private-practice series claims >60% benefit — compelling, but without a control arm, it cannot be verified. An MD Anderson team found 80% pain response in 20 cancer patients in 2025.
What the law says: Off-label. No cancer indication approved at any dose. No FDA safety alerts or medical board actions specifically targeting LDN for cancer use. Legal to prescribe, compound, and take. Insurance rarely covers it. Most patients pay $30-50/month out of pocket.
The funding reality: The reason no Phase 3 trial exists is economic, not scientific. A 40-year-old generic with no patent offers no return on a $300M trial investment. That's a funding finding — not evidence it doesn't work. The evidence gap is real; the reason for that gap is important context for how to interpret it.
- LDN's mechanism (OGF-OGFr axis + immune modulation) is biologically plausible and well-documented preclinically — it is not pseudoscience
- The Duke RCT null result was on QoL/fatigue, not tumor response — a real finding that must be reported, but not the only relevant question
- Berkson's pancreatic cancer cases (ALA+LDN) document individual outcomes that cannot be explained away — and cannot establish causation in a single-arm case series
- The hard contraindication for anyone on opioids is not negotiable — it is the first question to answer before considering LDN in any cancer setting
- LDN's safety profile at 4.5 mg, based on decades of off-label use across multiple conditions, is genuinely reassuring — the opioid interaction is the primary risk in oncology patients
- A definitive answer requires a funded Phase 3 trial that will not happen unless academic or government funding steps in — and that is worth knowing when deciding how to read the evidence